Weekly update Companies AI-cruiter Recruiting service

Chroma Medicine

Founded: 2021

Location: Brookline, MA

Employee range: 50 - 200

Clinical stage: RD

Therapy area: Genetic diseases

Drug types: GEN

Lead product: Undisclosed

Product link: https://chromamedicine.com/science/

Funding: $135M B Mar 2023; $125M A Nov 2021

Investors: Atlas Venture, RCH Venture Partners, DCVC Bio, Mubadala Capital, Sixth Street, Alexandria Venture Investments, Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Newpath Partners, Omega Funds, Osage University Partners, Sofinnova Partners, T Rowe Price, Wellington Management

chromamedicine.com

linkedin.com

job board

Short description:

DNA modification therapy

Drug notes:

Long description:

Chroma Medicine is developing epigenetic medicines to revolutionize the treatment of genetic diseases. Epigenetics refers to the diverse ways in which the expression of genes can be regulated. Chroma is exploiting these natural gatekeeper mechanisms of gene expression to develop genomic medicines without changing the sequence of DNA. Chroma’s programmable epigenetic editors can target a specific genomic loci of therapeutic interest and either silence or activate the gene. The epigenetic changes made are specific and durable offering the potential for single-dose medicines. Chroma’s programmable and modular platform positions them to many therapeutic possibilities for which they hope to cure patients suffering from serious illnesses.